-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-199 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-199 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-199 in Solid Tumor Drug Details: PT-199 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NoNO-42 in Acute Ischemic Stroke
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NoNO-42 in Acute Ischemic Stroke Drug Details: NoNO-42 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APIRx-1603 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APIRx-1603 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.APIRx-1603 in Atopic Dermatitis (Atopic Eczema) Drug Details: APIRx-1603 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-343 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-343 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IBI-343 in Solid Tumor Drug Details:IBI-343 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BR-790 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BR-790 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BR-790 in Head And Neck Cancer Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APIRx-1602 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APIRx-1602 in Psoriasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APIRx-1602 in Psoriasis Drug Details: APIRx-1602 (AX-1602) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APIRx-1601 in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APIRx-1601 in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APIRx-1601 in Vitiligo Drug Details: APIRx-1601 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ReneCann in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ReneCann in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ReneCann in PsoriasisDrug Details:APIRx-1602 (AX-1602) is under development for the treatment of psoriasis. It...